Published in the New England Journal of Medicine (2008), the CAMMS223 trial provides critical insights into the efficacy of Alemtuzumab compared to Interferon Beta-1a in patients with early, relapsing-remitting multiple sclerosis (RRMS). This phase 2, randomized, blinded study highlights the … Read More
multiple sclerosis
MS-SMART Trial: Neuroprotection in Multiple Sclerosis
MS-SMART Trial: Evaluating Neuroprotection in Secondary Progressive Multiple Sclerosis Secondary progressive multiple sclerosis (SPMS) remains one of the most challenging forms of MS to treat, as no effective therapies currently exist to halt disease progression. The MS-SMART trial (2020) was … Read More